Robert T Galvin (Robert Galvin)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Gene Expression

Top Venues

Current oncology reports

Neuro-oncology advances

This page only lists publications with an associated author ORCID identifier.

Publications

Danielle Maeser, Robert F Gruener, Robert T Galvin, Adam Lee, Tomoyuki Koga, Florina-Nicoleta Grigore, Yuta Suzuki, Frank B Furnari, Clark Chen, Rong Stephanie Huang
Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma. Cancers 16 (9) (2024)
Danielle Maeser, Robert F Gruener, Robert T Galvin, Adam Lee, Tomoyuki Koga, Florina-Nicoleta Grigore, Yuta Suzuki, Frank B Furnari, Clark Chen, Rong Stephanie Huang
Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma. Cancers 16 (9) (2024)
Danielle Maeser, Robert F Gruener, Robert T Galvin, Adam Lee, Tomoyuki Koga, Florina-Nicoleta Grigore, Yuta Suzuki, Frank B Furnari, Clark Chen, Rong Stephanie Huang
Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma. Cancers 16 (9) (2024)
Robert T Galvin, Cynthia Zheng, Garrett Fitzpatrick, Colleen L Forster, Carolina Sandoval-Garcia, Daniel Guillaume, Ahmed Elbermawy, Andrew Cook Nelson, Can Özütemiz, Liam Chen, Christopher L Moertel
MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma. Neuro-oncology advances 5 (1) (2023)
Robert T Galvin, Sampreeti Jena, Danielle Maeser, Robert F Gruener, Rong Stephanie Huang
Revealing Pan-Histology Immunomodulatory Targets in Pediatric Central Nervous System Tumors. Cancers 15 (22) (2023)
Robert T Galvin, Adrienne L Watson, David A Largaespada, Nancy Ratner, Sara Osum, Christopher L Moertel
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current oncology reports 23 (4) (2021)